W ten Bokkel Huinink

Summary

Affiliation: The Netherlands Cancer Institute
Country: The Netherlands

Publications

  1. ncbi Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
    W ten Bokkel Huinink
    The Netherlands Cancer Institute, Amsterdam
    J Clin Oncol 15:2183-93. 1997
  2. ncbi Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy
    W W ten Bokkel Huinink
    The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Med Oncol 15:174-82. 1998
  3. ncbi Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer
    W W ten Bokkel Huinink
    The Netherlands Cancer Institute, Amsterdam
    Lung Cancer 26:85-94. 1999
  4. ncbi Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma
    W ten Bokkel Huinink
    The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Ann Oncol 15:100-3. 2004
  5. ncbi Phase II study of fotemustine in patients with advanced ovarian carcinoma. A trial of the EORTC Gynecological Cancer Group
    M S Aapro
    Division of Medical Oncology, Clinique de Genolier, Geneva 1272, Switzerland
    Eur J Cancer 39:1141-3. 2003
  6. ncbi Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group
    M S Aapro
    Division d Oncologie, Hopital Cantonal Universitaire, Geneve, Switzerland
    Ann Oncol 14:441-8. 2003

Detail Information

Publications6

  1. ncbi Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
    W ten Bokkel Huinink
    The Netherlands Cancer Institute, Amsterdam
    J Clin Oncol 15:2183-93. 1997
    ..Topotecan and paclitaxel were evaluated in a randomized, multicenter study of patients with advanced epithelial ovarian carcinoma who had progressed during or after one platinum-based regimen...
  2. ncbi Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy
    W W ten Bokkel Huinink
    The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Med Oncol 15:174-82. 1998
    ..A starting dose of 150 U/kg of rhEPO, three times a week, may be recommended...
  3. ncbi Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer
    W W ten Bokkel Huinink
    The Netherlands Cancer Institute, Amsterdam
    Lung Cancer 26:85-94. 1999
    ..locally advanced or metastatic NSCLC and good performance status, and that it is better tolerated than the combination cisplatin/ etoposide...
  4. ncbi Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma
    W ten Bokkel Huinink
    The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Ann Oncol 15:100-3. 2004
    ....
  5. ncbi Phase II study of fotemustine in patients with advanced ovarian carcinoma. A trial of the EORTC Gynecological Cancer Group
    M S Aapro
    Division of Medical Oncology, Clinique de Genolier, Geneva 1272, Switzerland
    Eur J Cancer 39:1141-3. 2003
    ..Therefore, no role has been demonstrated in our cohort for the use of fotemustine, a nitrosourea, in pretreated ovarian cancer...
  6. ncbi Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group
    M S Aapro
    Division d Oncologie, Hopital Cantonal Universitaire, Geneve, Switzerland
    Ann Oncol 14:441-8. 2003
    ....